Proteome Sciences has developed in-vitro assays to treat allergies associated with the skin and respiratory system that are induced by chemical compounds and substances.

Using PS Biomarker Services platform, Proteome identified and filed patents for more than 100 biomarkers from cells in the immune system and another 100 biomarkers from skin cells.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Proteome Sciences chief executive Christopher Pearce said that the eight TMT-SRM assays they selected have good performance and correlation with the discovery data.

"Most importantly, the biomarker assays developed provide an in-vitro alternative to animal testing that will become mandatory across the EU," Pearce said.

The company expects the biomarkers it has identified will lead to a number of industrial testing products and service contracts.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact